ESSENCE CS9 TIMI 73b is a phase 3 multicenter, randomized, double-blind, placebo-controlled trial in ~1320 patients to evaluate the safety and efficacy of olezarsen, an antisense oligonucleotide inhibitor of apoC-III production, administered subcutaneously to patients with either moderate hypertriglyceridemia and atherosclerotic cardiovascular disease (established or at increased risk for) or with severe hypertriglyceridemia. MAIN RESULTS:Targeting … Continue reading ESSENCE CS9 – TIMI 73b